DRC to launch first phase of Mpox vaccination campaign amid ongoing outbreak
13 oC
13 oC
Güneşli
13 oC
Güneşli
The Democratic Republic of the Congo (DRC), the "epicenter" of Africa's ongoing Mpox outbreak, will begin the first phase of its vaccination campaign on October 2, the government announced.
The campaign, which will run until October 11, follows the receipt of over 265,000 vaccine doses from international partners.
The DRC has reported 21,813 suspected cases of Mpox, with 716 deaths recorded since the beginning of 2024, according to a report released Friday by the Congolese Ministry of Health. The country is responsible for approximately 90 percent of Mpox cases across Africa.
The vaccination campaign comes as the World Health Organization (WHO) approved the MVA-BN vaccine, developed by Bavarian Nordic, for its prequalification list, marking it as the first officially approved vaccine for Mpox. (ILKHA)
LEGAL WARNING: All rights of the published news, photos and videos are reserved by İlke Haber Ajansı Basın Yayın San. Trade A.Ş. Under no circumstances can all or part of the news, photos and videos be used without a written contract or subscription.
The death toll from the ongoing Ebola outbreak in the Democratic Republic of the Congo (DRC) has surpassed 3,000, according to the latest figures released by the Congolese government, highlighting the rapidly expanding scale of the country’s deadliest Ebola epidemic on record.
Türkiye has brought together hundreds of representatives from government, local administrations, academia, civil society and the private sector in Istanbul to develop a comprehensive national roadmap for tackling plastic pollution and accelerating the country’s transition toward a circular economy.
The Democratic Republic of Congo has launched an emergency Ebola vaccination campaign as authorities race to contain the country’s deadliest recorded outbreak, with thousands of confirmed cases and deaths reported across multiple provinces.
Cuban scientists have reached a significant milestone in the country's decades-long effort to build an independent biotechnology and pharmaceutical sector, with an experimental cancer drug developed domestically now preparing to enter clinical testing in patients with advanced melanoma.
